Ac immune partner lmi progresses tau pet tracer pi-2620 into late-stage development in alzheimer's disease

Lausanne, switzerland, sept. 26, 2022 (globe newswire) -- ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partner, life molecular imaging (lmi), is moving pi-2620, the tau positron-emission tomography (pet) tracer, into late-stage clinical development in alzheimer's disease (ad). as part of the agreement with ac immune, lmi will make a milestone payment.
ACIU Ratings Summary
ACIU Quant Ranking